Cancer Immunotherapy Guidelines Committee

The Cancer Immunotherapy Guidelines Committee oversees the development of new disease-specific guidelines and updates for existing guidelines that provide guidance on the appropriate treatment algorithms and recommended administration of FDA-approved cancer immunotherapies as well as mitigating and managing adverse event.  The committee maintains standards for the SITC Cancer Immunotherapy Guidelines subcommittees to ensure the recommendations are unbiased, relevant and facilitate clinical decision-making leading to optimal patient care.

Cancer Immunotherapy Guidelines Subcommittees

The disease-specific Cancer Immunotherapy Guidelines Subcommittees monitor the advancements in the cancer immunotherapy treatment options as indicated by FDA approvals of agents and companion diagnostic tools to publish and update evidence-based manuscripts for the clinical care team to utilize as a set of guidelines for treatment indications in those specific disease area. These guidelines provide key indicators to help determine when the use of immunotherapy is appropriate for cancer patient treatment.